Use of domperidone and risk of serious cardiac events in postpartum women

Project number: 
18-085 D
Approval date: 
Thursday, August 23, 2018
Principal Investigator: 
Dormuth,Colin
Institution: 
University of British Columbia (UBC)
Funding Agency: 
Not Available
Datasets requested: 
Not available
Research objective: 

OBJECTIVES
a) To describe calendar time trends in the use of domperidone among postpartum women in BC.

b) To compare the demographic and clinical characteristics (including perinatal and peripartum characteristics) of women prescribed domperidone in the six months postpartum with those of women not prescribed it during this period.

c) To determine whether the use of domperidone is associated with an increased risk of a composite endpoint of VT and/or SCD among postpartum women in the six months following delivery.

d) To determine whether the use of domperidone is associated with increased risks of the individual endpoints of VT, SCD, and all-cause mortality among postpartum women in the six months following delivery.

e) To determine if the risk of a composite endpoint of SCD/VT varies with domperidone dose (

HYPOTHESES
a) Domperidone use has increased over time among postpartum women in BC.

b) Domperidone users will be more likely to be older, to be obese, to have comorbid chronic conditions, to have higher income, to be first-time mothers, to have multi-fetal gestation, to have preterm delivery, and to have had a caesarean delivery compared to non-users.

c) The use of domperidone will be associated with an increased risk of a composite endpoint of VT and SCD among postpartum women.

d) The use of domperidone will be associated with increased risks of the individual endpoints of VT, SCD, and all-cause mortality among postpartum women.

e) The association between domperidone use and a composite endpoint of VT and SCD will vary with dose and duration.


Page last revised: August 29, 2018